Neuroimaging of Opioid Phase (OPAL)

NCT ID: NCT05905419

Last Updated: 2025-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare activity in the brains of female adults with chronic pain and/or opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to determine differences in neurophysiology and behavior during different phases of opioid use in patients. Study activities will include neuroimaging (MRI and fMRI), behavioral tasks, sensory testing, blood draws, and questionnaires. The neuroimaging data will be analyzed using specialized software; data from questionnaires, sensory testing, and behavioral task performance will be analyzed using standard statistical software. Risks and safety concerns include standard, minimal risks associated with MRI scans, sensory testing, blood draws, and confidentiality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pain Opioid Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Female adults with chronic pain who take prescribed opioid medications

Opioid taking participants will undergo two study visits, one for each opioid phase ("peak" or "trough")

Group Type EXPERIMENTAL

Opioid Phase

Intervention Type OTHER

Opioid-taking patients are assigned to take their prescribed opioid medication before ("peak" opioid phase) during 1 scan and after ("trough" opioid phase) during the other MRI scan

Female adults with chronic pain who do not take opioid medications

Participants with chronic pain who are not taking opioids will undergo one study visit

Group Type NO_INTERVENTION

No interventions assigned to this group

Healthy controls

Healthy female participants who are not taking opioids will undergo one study visit

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Opioid Phase

Opioid-taking patients are assigned to take their prescribed opioid medication before ("peak" opioid phase) during 1 scan and after ("trough" opioid phase) during the other MRI scan

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. female and ages 18+
2. ability to read/understand English and give consent to participate
3. no current or history of chronic pain
4. not regularly taking any pain-relieving or mood-altering medications (per PI discretion)
5. absence of use of opioid medications


1. female and ages 18 +
2. ability to read/understand English and give consent to participate
3. self-reported or physician diagnosis of fibromyalgia and/or chronic pain
4. current use of opioid medication(s) for inclusion in the opioid patient group -OR- absence of use of opioid medications for inclusion in the non-opioid patient group

Exclusion Criteria

1. limited ability to participate fully in behavioral tasks, longitudinal follow-up
2. MRI contraindication
3. any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study
4. male
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katherine T Martucci, PhD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duke University Medical Center

Durham, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

HAPN Lab Manager

Role: CONTACT

919-684-2758

Angelina Xiong, BS

Role: CONTACT

919-684-3136

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

HAPN Lab Manager

Role: primary

919-684-2758

Related Links

Access external resources that provide additional context or updates about the study.

https://anesthesiology.duke.edu/research/martucci-lab

Human Affect \& Pain Laboratory (Duke Chronic Pain Lab)

https://redcap.duke.edu/redcap/surveys/?s=RXCMMCPWNKWJELN4

Please complete this survey as a first step to join the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01DA055850

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00110253

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neurobiology of Opioid Dependence: 4 - 4
NCT00000195 WITHDRAWN PHASE2
OMAR Opioid Use Disorder
NCT05683184 RECRUITING PHASE1
Tau PET Imaging in Opioid Use Disorder
NCT05651516 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Oxytocin Treatment of Opioid Dependence
NCT02548728 COMPLETED PHASE1/PHASE2
Buprenorphine for Cancer Pain
NCT05910190 UNKNOWN PHASE4